Redeye views the Q3 report as relatively uneventful, apart from the apparent successful launch of Terclara in Sweden. The slightly better sales and strong gross margin are, of course, positive in themselves. Focusing on the upcoming top-line data from the Phase 3 study is natural at this point. There was no additional news regarding this, and we have to wait for the data at the end of December. The Base case remains at SEK 19(19) per share.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/